Insights
Insights From Our Experts
Articles
4th Annual Brand Planning Report: Fueling Brand Plan Success Through AI‑Powered Integration
Cross‑functional integration and data‑driven strategy remain top priorities for brand leaders, but for many organizations, they’re still difficult to achieve. In our fourth annual report, Chief Strategy Officer at EVERSANA INTOUCH, John Kenny, and Senior Partner of EVERSANA MANAGEMENT CONSULTING, Sean Rapson, explore the state of brand…
Why Women’s Health Is at an Inflection Point and Why Commercialization Must Catch Up
Women’s health is undergoing a long‑overdue transformation. After decades of chronic underfunding, investment in women’s health has accelerated dramatically with capital surging more than 300% in 2018 and then tripling again between 2019 and 2024. Innovation…
Webinar Recording | From MFPs to MFN: Navigating the New Rules of Drug Pricing in 2026
In this recent webinar, experts John Neal, Katya Svoboda, and David Byram examine the major policy shifts transforming the U.S. drug pricing landscape—including the accelerating impact of MFN models, evolving MFPs, PBM transparency reforms, and the…
Gartner Is Right — About the Wrong Kind of Agency AI Platform
Gartner’s warning isn’t anti‑AI—it’s anti‑dependency. The distinction will define which agencies remain relevant by the end of the decade. A recent Gartner study predicts open-source platforms will support more than 75% of enterprise AI deployments by 2028, and their concern about CMOs getting locked…
Advancing Medical Affairs Through Data and Scientific Communications: Key Takeaways from DIA MASC 2026
At the 2026 DIA Medical Affairs and Scientific Communications (MASC) Forum, EVERSANA shared new thought leadership focused on how medical affairs teams can strengthen decision‑making, optimize operations, and elevate scientific communications in an increasingly data‑driven environment.…
Scaling Practical AI Across Commercial Teams
EVERSANA’s AI journey began with classic predictive modeling but its evolution into an enterprise-wide strategy is rooted in something deeper: a trusted data foundation and rigorous change management. Drew McCormick, Head of Data & Analytics at EVERSANA, explains how…
Key Implications of Recent U.S. PBM Reforms
PBM Reform Is Here—What It Means for Manufacturers and Plan Sponsors Recent U.S. policy actions are reshaping the pharmacy benefit manager landscape. New federal legislation, a proposed Department of Labor rule, and a landmark FTC settlement…
Building a scalable GLP-1 care model
The rapid rise of GLP‑1 therapies has revealed a fundamental challenge across healthcare. For many patients, the pathway to their first prescription is not a single, unified entry point. It’s a maze of primary care visits, telehealth platforms,…
Navigating the Intersection of AI, Global Commercialization and Patient Value
Artificial intelligence is reshaping the life sciences industry, but meaningful progress comes when technology is paired with human judgment, regulatory discipline and a clear focus on patient value. In a recent EU Startup News interview, our own Faruk Capan,…
Recognizing Rare Disease Day: Advancing Hope, Access and Innovation
On Rare Disease Day, we recognize the more than 300 million people worldwide living with rare conditions—individuals who often face long diagnostic journeys, limited treatment options, and barriers to consistent care. At EVERSANA, supporting this community is…